McMillan Shakespeare in trading halt due to proposed changes to salary packaging

Will the brutal share price drop continue?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Salary packaging services company McMillan Shakespeare (ASX: MMS) is in trading halt due to proposed changes to salary packaging announced earlier this week that would limit people from claiming a tax deduction for the private use of business cars.

Changes on the federal level have always been a risk to the company, and investors were aware of it — proposed changes have caused jitters in the past. The company has asked for the trading halt until it can examine the impact the proposed changes and make an announcement regarding the impact.

The real story here is that McMillan Shakespeare was an overvalued stock, and management has done a good job emphasizing growth. For example, when interest rates are falling, management presentations emphasize growth rates if you adjust for the lower interest earned from the float (the implied growth rate being higher). On the flipside, when interest rates were on the way up, the company did not draw attention to how this boosts growth.

The board and management have managed to sell over $120 million worth of shares and options since September 2010. The company has disclosed that directors were disposing of shares or options on 14 separate occasions since that time. There were no on-market purchases by insiders. Interestingly, the company never bothered to correct the typo on this Change of Director's Interest Notice that implies John Bennetts sold $1,394.80 worth of shares rather than $1.39 million.

If the proposed changes are implemented, the salary packaging services industry is no doubt in for a shock. Typically, industry-wide challenges provide opportunities for stronger companies to acquire the weaker ones. However, since McMillan Shakespeare expanded into "Asset Management" it is straddled with debt. It has about $189 million of debt on the books and only $55 million in cash. I don't think it is in a strong position to acquire its competitors.

The "Asset Management" part of the business finances the cars that are leased as part of a salary package. The company now has $282 million of assets under management on the balance sheet. It will be interesting to see if it can resell the cars for that amount. If so, the balance sheet might be OK.

Either way, I think the company is overvalued. It earned about 75 cents per share in 2012 and last traded at $15.36. It is important to look at per share statistics due to the dilution caused by the exercise of options. Between 2010 and 2012, shares on issue increased from 67.7 million to 74.5 million.

Even if the changes to salary packaging do not go through, the risk that the rules will change will not go away. That's because under the current system people are (in effect) allowed to claim tax deductions for cars that are used mostly for personal tasks. If you forecast earnings to be 90 cents per share this year and were happy to pay a P/E of 14, then you would still only pay $12.60 for each share in this company. Personally, I wouldn't even buy at that price.

Foolish takeaway

Long-term investors should consider whether management share the same faith in the business that they do. Watch out for consistent insider selling and be aware of the fact that directors probably understand the business better than you do. Look for companies that have cash ready when opportunities arise and don't buy simply because the share price is going up.

Interested in our #1 dividend-paying stock? Discover The Motley Fool's favourite income idea for 2013-2014 in our brand-new, FREE research report, including a full investment analysis! Simply click here for your FREE copy of "The Motley Fool's Top Dividend Stock for 2013-2014."

More reading


 Motley Fool contributor Claude Walker has an indirect interest in McMillan Shakespeare through a managed fund. Find him on Twitter @claudedwalker

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »